000129837 001__ 129837 000129837 005__ 20240112163658.0 000129837 0247_ $$2doi$$a10.3389/fgene.2012.00273 000129837 0248_ $$2sideral$$a80850 000129837 037__ $$aART-2012-80850 000129837 041__ $$aeng 000129837 100__ $$aAgúndez, J. A. G. 000129837 245__ $$aToward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain 000129837 260__ $$c2012 000129837 5060_ $$aAccess copy available to the general public$$fUnrestricted 000129837 5203_ $$aThe development of clinical practice recommendation sor guide lines forthe clinical use of biomarkersis an issue of great importance with regard to averse drug reactions. Thepoten-tial of pharmacogenomic biomarkers has been extensively investigate dinrecent years. However, several barriers to implementing the use of pharmacogenomics testing exist. We conducted asurvey among members of the Spanish Societies of Pharmacology and Clinical Pharmacology to obtain in format in about the perception of uch barrier sand to compare the perceptions of participants about the relative importance of ma jorgene/drug pairs. Of 11 potential barriers, the highest importance was attributed to lack of institutional support for pharmacogenomics testing, and to the issues related to the lackof guidelines. Of the proposed gene/drug pairs the highest importance was as signed to HLA-B/abacavir, UGT1A1/irinotecan, andCYP2D6/tamoxifen. In this perspective article, we compare there lative importanceof 29 gene /drug pairs in the Spanish study witht hat of the same pair sinthe American Society for Clinical Pharmacology and Therapeutics study, and we provide suggestions and area soffocus to developaguide for clinical practice in pharmacogenomics testing. 000129837 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/FPI-CSD2009-00064$$9info:eu-repo/grantAgreement/ES/MICINN/ISCIII-PS09-00469$$9info:eu-repo/grantAgreement/ES/MICINN/ISCIII-PS09-00943 000129837 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000129837 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion 000129837 700__ $$aAbad-Santos, F. 000129837 700__ $$aAldea, A. 000129837 700__ $$aAlonso-Navarro, H. 000129837 700__ $$0(orcid)0000-0002-8222-1418$$aBernal, M. L.$$uUniversidad de Zaragoza 000129837 700__ $$aBorobia, A. M. 000129837 700__ $$aBorrás, E. 000129837 700__ $$aCarballo, M. 000129837 700__ $$aCarvajal, A. 000129837 700__ $$aGarcía-Muñiz, J. D. 000129837 700__ $$aGervasini,G. 000129837 700__ $$aJiménez-Jiménez,F. J. 000129837 700__ $$aLucena,M. I. 000129837 700__ $$aMartínez,C. 000129837 700__ $$aSacristán,J. A. 000129837 700__ $$aSalado,I. 000129837 700__ $$aSinués,B. 000129837 700__ $$0(orcid)0000-0003-4629-6743$$aVicente,J.$$uUniversidad de Zaragoza 000129837 700__ $$aGarcía-Martín,E. 000129837 7102_ $$11005$$2315$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Farmacología 000129837 773__ $$g3, 273 (2012), 1-4$$pFront. genet.$$tFrontiers in Genetics$$x1664-8021 000129837 8564_ $$s814897$$uhttps://zaguan.unizar.es/record/129837/files/texto_completo.pdf$$yPostprint 000129837 8564_ $$s3048128$$uhttps://zaguan.unizar.es/record/129837/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint 000129837 909CO $$ooai:zaguan.unizar.es:129837$$particulos$$pdriver 000129837 951__ $$a2024-01-12-14:07:12 000129837 980__ $$aARTICLE